Stock Rating Report for AIS

Ticker: 

Stock Information

Ticker AIS
Company Name Antares Pharma Inc
Current Price $2.68
Previous Close $2.68
Industry Medical Instruments and Supplies
Sector HEALTHCARE
Long Stop Loss Members Only
Short Stop Loss Members Only
Expected Move Members Only
Optionable? Yes

StockProphet Ratings

Join today to see our Technical, Fundamental, and Composite Stock Rating for this stock.

Sector Risks

Sign up for MarketProphet today to see our 30, 60, and 90 day risk assessment for this stock.


Chart

We use technical analysis and fundamental analysis to recommend ratings for thousands of stocks. If you had a subscription, this space would show our 3 year history of trades for AIS. However, we only show it to our subscribers.

We update our ratings and stop losses EVERY WEEK.

Don't miss out on what we recommend for Antares Pharma Inc next week. Sign up today and start making money!

Demand Fundamentals

Demand Fundamental Value Score Rating
Qtr/Qtr Revenue Growth Members Only
Qtr/Qtr Earnings Growth Members Only
Year/Year Revenue Growth Members Only
Year/Year Earnings Growth Members Only
Multi-Year Revenue Growth Members Only
Multi-Year Earnings Growth Members Only
Relative PE Ranking Members Only
Return on Equity Members Only
Yield Members Only
Institutional Holding Members Only
Stock Price Members Only
Relative Fundamental Ranking Members Only
Total Score Members Only

Demand Technicals

Demand Technical Value Score Rating
Recommended Condition Members Only
Trading Zone Members Only
Average Trading Volume Members Only
Industry Bull/Bear Condition Members Only
Sector Bull/Bear Condition Members Only
Current Signal Start Date Members Only
Total Score Members Only

Company Profile

Antares Pharma, Inc., a pharmaceutical company, focuses on self-injection pharmaceutical products and technologies, and topical gel-based products. It offers injection devices, which include Zomajet 2 Vision, Zomajet Vision X, Twin-Jector EZ II, and Tjet for human growth hormone- Medi-Jector Vision for insulin- Vibex disposable pressure assisted auto injectors that enables a controlled pressure delivery of drugs into the body utilizing a spring power source- and disposable pen injectors, which are needle-based devices designed to deliver multiple injections from multi-dose drug cartridges. The company also provides Anturol, an oxybutynin ATD (advanced transdermal delivery)gel, which is in Phase III clinical trials for the treatment of overactive bladder- Elestrin, a transdermal estradiol gel for the treatment of moderate-to-severe vasomotor symptoms associated with menopause- LibiGel, a transdermal testosterone gel that is in Phase III clinical studies for the treatment of female sexual dysfunction- and Nestorone contraceptive formulation products, which has completed Phase II clinical trials. Antares Pharma, Inc. markets its products to pharmaceutical companies primarily in the United States and Europe. It has collaborative arrangements and license agreements with Teva Pharmaceutical Industries, Ltd.- Ferring Pharmaceuticals BV- JCR Pharmaceuticals Co., Ltd.- BioSante Pharmaceuticals, Inc.- Jazz Pharmaceuticals- and Population Council. The company was founded in 1979 and is based in Ewing, New Jersey.


Latest News

Fri, 03 Feb 2012 22:33:50 GMT3 Hot Picks On The Way Up
Thu, 02 Feb 2012 15:25:46 GMTAntares's Promising New RA Treatment Method Revisited
Wed, 01 Feb 2012 15:33:51 GMTOn The Fly: Analyst Upgrade Summary
Tue, 31 Jan 2012 20:58:12 GMTInvestors Need To Know Why Antares Will Have Exponential Growth In 2012
Tue, 31 Jan 2012 20:51:15 GMTSmall Biotech Companies With Big, Promising Pipelines
Tue, 31 Jan 2012 08:27:54 GMTTop Q4 Undervalued Buys And Sells Of Vanguard's $632 Billion In 13-F Assets
Mon, 30 Jan 2012 22:52:17 GMTAntares's New RA Treatment Method Has Large Market Potential
Fri, 27 Jan 2012 20:06:53 GMTAnturol Equals A Triple-Digit PPS Jump In Antares's Share Price, Here's Why
Thu, 26 Jan 2012 11:13:46 GMTTeva Partnership And Pipeline Potential: Why Antares Is A Buy
Wed, 25 Jan 2012 20:41:09 GMTWall Street's Best Hidden Stocks
Wed, 25 Jan 2012 13:20:00 GMTAntares Pharma and Boston Scientific Benefit From Renewed Industry Optimism
Wed, 25 Jan 2012 02:51:57 GMTStock Boards: Weeding Through The Nonsense, Getting To The Facts.
Tue, 24 Jan 2012 21:43:21 GMT4 Low-Priced Biotech Stocks Poised To Rally In 2012
Mon, 23 Jan 2012 21:03:44 GMTInvesting In Small Cap Bio-Pharma: Striking It Rich Or Going Bust
Mon, 23 Jan 2012 18:02:53 GMTThe Best Biotech Stocks Of 2012
Mon, 23 Jan 2012 17:31:20 GMTTop Three 'Penny-Land' Biotech Stock Picks
Sat, 21 Jan 2012 02:41:24 GMTBuy, Sell, or Hold: Antares Pharma
Wed, 18 Jan 2012 19:34:57 GMTA Bio-Pharma Buy And Sell List: Part 2
Wed, 18 Jan 2012 19:33:35 GMTA Bio-Pharma Buy And Sell List: Part 1
Tue, 17 Jan 2012 18:58:42 GMTAcorda Therapeutics: A Mid Cap Bio-Pharma Poised For Big Long Term Returns
News provided by Yahoo! Finance